It initially received FDA approval in 2014 for the treatment of metastatic gastric cancer in the second line setting and most recently received FDA approval in 2020 for the first‐line treatment of metastatic EGFR‐mutated non‐small cell lung cancer. This evidence concerns the gene EGFR and lung cancer.